A Phase 1 interventional study of Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg and Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg in Locally Advanced or Metastatic Breast Cancer, sponsored by R-Pharm. Terminated at 3 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-10.
Sponsored by R-Pharm · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies testing ixabepilone in Breast Neoplasms — none open to participants now, 1 under way, none of them phase 3. ixabepilone · Breast Neoplasms.
Among the 41 studies testing ixabepilone in Breast Neoplasms, this one is the 34th largest by enrollment of the 39 interventional ones that give a count, is one of 11 that started in 2008, is one of 7 in phase 1, and was the 18th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →None of the 41 studies testing ixabepilone in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →
ixabepilone: first FDA approval 2007 (IXEMPRA KIT). What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 29 · Phase 3 5
First in 2000; this study’s year is marked. 11 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 56 across the 39 interventional studies. Of the 38 that completed or were terminated, 28 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 41 have an industry lead sponsor. The 10 most frequent:
R-Pharm is the lead sponsor of 58 studies on the registry; 2 are open to participants now.
15 studies in Breast Neoplasms by R-Pharm: none open now, 1 under way, 1 of them phase 3. Of 13 finished, 10 (77%) have results posted.
Among the 15 studies in Breast Neoplasms by R-Pharm, this one is the 13th largest by enrollment of the 14 interventional ones that give a count, is one of 6 that started in 2008, is one of 4 in phase 1, and was the 11th registered.
R-Pharm’s Breast Neoplasms studies by the year they started, since 2002.
1 of the studies testing ixabepilone in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00877500M.D. Anderson Cancer CenterIxabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 41 studies testing ixabepilone in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among R-Pharm’s 15 in Breast Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety and preliminary effectiveness of ixabepilone plus lapatinib with and without capecitabine in the treatment of human epidermal growth factor receptor 2 (HER2)-positive or metastatic breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose Level 1
Drug: Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg
Dose Level 2
Drug: Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg
Dose Level 3
Drug: Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg
Triplet Combination
Drug: Ixabepilone + Lapatinib + Capecitabine
Drug page: Ixabepilone
Lapatinib, 1000 mg, administered orally, once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone (Day 1). Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m\^2, administered as a 3-hour IV infusion. Lapatinib, 1000 mg, administered orally, once a day, every day, for a 21-day cycle.
Drug page: Ixabepilone
Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m\^2 + lapatinib, 1000 mg). Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone. Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m\^2, administered as a 3-hour IV infusion. Lapatinib administered, 1250 mg, orally, once a day, every day, for a 21-day cycle.
Drug page: Ixabepilone
Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m\^2 + lapatinib, 1250 mg). Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone. Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 40 mg/m\^2, administered as a 3-hour IV infusion. Lapatinib, 1250 mg, administered orally, once a day, every day, for a 21-day cycle.
Drug pages: Ixabepilone · Lapatinib · Capecitabine
Planned escalating doses of the triplet combination of ixabepilone, lapatinib, and capecitabine. No participants were enrolled in this arm due to premature termination of the study.
Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D) of Ixabepilone When Administered With Lapatinib
The MTD is defined as the maximum dose that can be administered to 6 participants such that no more than 1 (or fewer than one third if more than 6 participants receive treatment) experiences a dose-limiting toxicity (DLT), with at least 2 experiencing a DLT at the next higher dose level. The RP2D is based on the MTD and the assessment of any relevant chronic toxicities.
Time frame: Days 1 through 21
MTD and RP2D of Ixabepilone When Administered With Lapatinib Plus Capecitabine
MTD is defined as the maximum dose that can be administered to 6 participants such that no more than 1 (or fewer than one third if more than 6 participants receive treatment) experiences a DLT, with at least 2 experiencing a DLT at the next higher dose level. The RP2D is based on the MTD and the assessment of any relevant chronic toxicities.
Time frame: Days 1 through 21
Number of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, Treatment-related AEs, Treatment-related AEs (Grade 3 or 4), Peripheral Neuropathy (PN), PN (Grade 3 or 4)
AE=Any new untoward medical event or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical event that results in death, persistent or significant disability/incapacity, drug dependency or abuse; is life-threatening, important, a congenital anomaly/birth defect; or requires or prolongs existing hospitalization. Treatment related=possibly, probably, or certainly related to and of unknown relationship to study treatment. Common Terminology Criteria (CTC) Grade 3=severe; Grade 4=life-threatening or disabling.
Time frame: Baseline to Day 21, continuously
Number of Participants With DLT
DLT=Any of the following events, attributable to study drug and occurring within 21 days after ixabepilone administration: Grade 3 or 4 nausea, vomiting, or diarrhea despite the use of adequate medical intervention; other Grade 3 or greater nonhematologic toxicity requiring removal from study drug; recovery from study drug-related toxicity that delayed scheduled retreatment for longer than 3 weeks; Grade 4 neutropenia for 5 or more consecutive days or Grade 3 or 4 neutropenia of any duration with sepsis or fever; thrombocytopenia or bleeding requiring platelet transfusion.
Time frame: Baseline to Day 21, continuously
Number of Participants With Abnormalities in Hematology Laboratory Results by Worst CTC Grade
CTC, Version 3.0 used to assess parameters. ULN=upper level of normal among all laboratory ranges. WBC (c/L): Grade (Gr)1:\<LLN to 3.0\*10\^9/L, Gr 2:\<3.0 to 2.0\*10\^9/L, Gr 3:\<2.0 to 1.0\*10\^9/L, Gr 4:\<1.0\*10\^9/L; ANC (c/uL): Gr 1:\<LLN to 1.5\*10\^9/L, Gr 2:\<1.5 to 1.0\*10\^9/L, Gr 3:\<1.0 to 0.5\*10\^9/L, Gr 4:\<0.5\*10\^9/L; Platelet count (c/uL): Gr 1:LLN to 75.0\*10\^9/L, Gr 2:\<75.0 to 50.0\*10\^9/L, Gr 3:\<50.0 to 25.0\*10\^9/L, Gr 4:\<25.0\*10\^9/L; Hemoglobin (g/dL): Gr 1:\<LLN to 10.0 g/dL, Gr 2:\<10.0 to 8.0 g/dL, Gr 3:\<8.0 to 6.5 g/dL, Gr 4:\<6.5 g/dL.
Time frame: Baseline and weekly from Days 1 to 21 (Cycle 1)
Number of Participants With Abnormalities in Serum Chemistry Laboratory Results by Worst CTC Grade
CTC, Version 3.0 used to assess parameters. ULN=upper level of normal among all laboratory ranges. ALT(U/L) Gr 1:\>ULN-2.5\*ULN,Gr 2:\>2.5-5.0\*ULN,Gr 3:\>5.0-20.0\*ULN,Gr 4:\>20.0\* ULN; AST(U/L) Gr 1:\>ULN-2.5\* ULN,Gr 2:\>2.5-5.0\*ULN,Gr 3:\>5.0-20.0\*ULN,Gr 4:\>20.0\* ULN; ALP(U/L)Gr 1:\>ULN-2.5\*ULN, Gr 2:\>2.5-5.0\*ULN, Gr 3:\>5.0-20.0\*ULN, Gr 4:\>20.0\*ULN; Creatinine (mg/dL): Gr 1:\>ULN-1.5\*ULN, Gr 2:\>1.5-3.0\*ULN, Gr 3:\>3.0-6.0\*ULN, Gr 4:\>6.0\*ULN; Total bilirubin (mg/dL): Gr 1:\>ULN-1.5\*ULN, Gr 2:\>1.5-3.0\*ULN, Gr 3:\>3.0-10.0\*ULN, Gr 4:\>10.0\*ULN
Time frame: At baseline and within 72 hours of Day 1 of 21-day cycle
Maximum Concentration of Ixabepilone
Time frame: Day 1 of 21-day cycle
Area Under the Concentration-time Curve From 0 to Infinity (AUC[INF]) and AUC From 0 to Last Quantifiable Concentration (AUC[O-T] of Ixabepilone
Time frame: Day 1 of 21-day cycle
Terminal Half-life of Ixabepilone
Time frame: Day 1 of 21-day cycle
Time to Peak Concentration of Ixabepilone
Time frame: Day 1 of 21-day cycle
Volume of Distribution at Steady State of Ixabepilone
Time frame: Day 1 of 21-day cycle
Overall Tumor Response By Number of Participants
Target lesion criteria: Complete Response(CR)=Disappearance of all clinical and radiologic evidence of target lesions; Partial Response (PR)=A 30% or greater decrease in the sum of longest diameter(LD) of all lesions in reference to the baseline sum LD. Stable Disease (SD)=Insufficient increase to qualify for Progressive Disease (PD) and insufficient shrinkage to qualify for PR; PD=A 20% or greater increase in the sum of LD of all target lesions, taking as reference the smallest sum LD recorded at or following baseline.
Time frame: Baseline and Day 21 (21-day cycle)
Duration of Response of Combination Treatment With Ixabepilone Plus Lapatinib
Duration of response is measured from the time in months that measurement criteria are first met for PR or CR, whichever is recorded first, until the date of documented PD or death. Participants who neither relapse nor die will be censored on the date of their last tumor assessment.
Time frame: First occurrence of PR or CR to PD or Death (no average, as no data available)
| Milestone | Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg | Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg | Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg | Ixabepilone+ Lapatinib + Capecitabine |
|---|---|---|---|---|
| Started | 6 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 6 | 0 | 0 | 0 |
| Withdrew: Disease progression | 2 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 3 | 0 | 0 | 0 |
| Milestone | Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg | Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg | Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg | Ixabepilone+ Lapatinib + Capecitabine |
|---|---|---|---|---|
| Started | 0 | 3 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 3 | 0 | 0 |
| Withdrew: Adverse event | 0 | 2 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 1 | 0 | 0 |
| Milestone | Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg | Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg | Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg | Ixabepilone+ Lapatinib + Capecitabine |
|---|---|---|---|---|
| Started | 0 | 0 | 1 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 1 | 0 |
| Milestone | Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg | Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg | Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg | Ixabepilone+ Lapatinib + Capecitabine |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
The MTD is defined as the maximum dose that can be administered to 6 participants such that no more than 1 (or fewer than one third if more than 6 participants receive treatment) experiences a dose-limiting toxicity (DLT), with at least 2 experiencing a DLT at the next higher dose level. The RP2D is based on the MTD and the assessment of any relevant chronic toxicities.
No measurements were reported for this outcome.
AE=Any new untoward medical event or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical event that results in death, persistent or significant disability/incapacity, drug dependency or abuse; is life-threatening, important, a congenital anomaly/birth defect; or requires or prolongs existing hospitalization. Treatment related=possibly, probably, or certainly related to and of unknown relationship to study treatment. Common Terminology Criteria (CTC) Grade 3=severe; Grade 4=life-threatening or disabling.
| Participants | Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg/d | Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg/d | Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg/d | Ixabepilone + Lapatinib + Capecitabine |
|---|---|---|---|---|
| Death | 3 | 0 | 0 | — |
| SAEs | 2 | 0 | 1 | — |
| AEs leading to discontinuation | 3 | 2 | 0 | — |
| Treatment-related AEs | 6 | 3 | 1 | — |
| Treatment-related AEs (Grade 3 or 4) | 3 | 3 | 1 | — |
| PN | 4 | 2 | 0 | — |
| PN (Grade 3 or 4) | 1 | 1 | 0 | — |
DLT=Any of the following events, attributable to study drug and occurring within 21 days after ixabepilone administration: Grade 3 or 4 nausea, vomiting, or diarrhea despite the use of adequate medical intervention; other Grade 3 or greater nonhematologic toxicity requiring removal from study drug; recovery from study drug-related toxicity that delayed scheduled retreatment for longer than 3 weeks; Grade 4 neutropenia for 5 or more consecutive days or Grade 3 or 4 neutropenia of any duration with sepsis or fever; thrombocytopenia or bleeding requiring platelet transfusion.
| Participants | Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg/d | Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg/d | Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg/d | Ixabepilone + Lapatinib + Capecitabine |
|---|---|---|---|---|
| Number of Participants With DLT | 1 | 0 | 0 | — |
CTC, Version 3.0 used to assess parameters. ULN=upper level of normal among all laboratory ranges. WBC (c/L): Grade (Gr)1:\<LLN to 3.0\*10\^9/L, Gr 2:\<3.0 to 2.0\*10\^9/L, Gr 3:\<2.0 to 1.0\*10\^9/L, Gr 4:\<1.0\*10\^9/L; ANC (c/uL): Gr 1:\<LLN to 1.5\*10\^9/L, Gr 2:\<1.5 to 1.0\*10\^9/L, Gr 3:\<1.0 to 0.5\*10\^9/L, Gr 4:\<0.5\*10\^9/L; Platelet count (c/uL): Gr 1:LLN to 75.0\*10\^9/L, Gr 2:\<75.0 to 50.0\*10\^9/L, Gr 3:\<50.0 to 25.0\*10\^9/L, Gr 4:\<25.0\*10\^9/L; Hemoglobin (g/dL): Gr 1:\<LLN to 10.0 g/dL, Gr 2:\<10.0 to 8.0 g/dL, Gr 3:\<8.0 to 6.5 g/dL, Gr 4:\<6.5 g/dL.
| Participants | Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg/d | Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg/d | Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg/d | Ixabepilone + Lapatinib + Capecitabine |
|---|---|---|---|---|
| White blood cell count (WBC) (Grade 1) | 1 | 0 | 1 | — |
| WBC (Grade 2) | 1 | 0 | 0 | — |
| WBC (Grade 3) | 2 | 3 | 0 | — |
| WBC (Grade 4) | 1 | 0 | 0 | — |
| Absolute neutrophil count (ANC) (Grade 1) | 0 | 0 | 0 | — |
| ANC (Grade 2) | 1 | 0 | 0 | — |
| ANC (Grade 3) | 2 | 1 | 0 | — |
| ANC (Grade 4) | 2 | 2 | 0 | — |
| Platelet count (Grade 1) | 1 | 1 | 2 | — |
| Platelet count (Grade 2) | 0 | 0 | 0 | — |
| Platelet count (Grade 3) | 0 | 0 | 0 | — |
| Platelet count (Grade 4) | 0 | 0 | 0 | — |
| Hemoglobin (Grade 1) | 3 | 3 | 6 | — |
| Hemoglobin (Grade 2) | 3 | 0 | 4 | — |
| Hemoglobin (Grade 3) | 0 | 0 | 0 | — |
| Hemoglobin (Grade 4) | 0 | 0 | 0 | — |
CTC, Version 3.0 used to assess parameters. ULN=upper level of normal among all laboratory ranges. ALT(U/L) Gr 1:\>ULN-2.5\*ULN,Gr 2:\>2.5-5.0\*ULN,Gr 3:\>5.0-20.0\*ULN,Gr 4:\>20.0\* ULN; AST(U/L) Gr 1:\>ULN-2.5\* ULN,Gr 2:\>2.5-5.0\*ULN,Gr 3:\>5.0-20.0\*ULN,Gr 4:\>20.0\* ULN; ALP(U/L)Gr 1:\>ULN-2.5\*ULN, Gr 2:\>2.5-5.0\*ULN, Gr 3:\>5.0-20.0\*ULN, Gr 4:\>20.0\*ULN; Creatinine (mg/dL): Gr 1:\>ULN-1.5\*ULN, Gr 2:\>1.5-3.0\*ULN, Gr 3:\>3.0-6.0\*ULN, Gr 4:\>6.0\*ULN; Total bilirubin (mg/dL): Gr 1:\>ULN-1.5\*ULN, Gr 2:\>1.5-3.0\*ULN, Gr 3:\>3.0-10.0\*ULN, Gr 4:\>10.0\*ULN
| Participants | Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg/d | Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg/d | Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg/d | Ixabepilone + Lapatinib + Capecitabine |
|---|---|---|---|---|
| Alanine aminotransferase (ALT) (Grade 1) | 1 | 0 | 0 | — |
| ALT (Grade 2) | 0 | 0 | 0 | — |
| ALT (Grade 3) | 0 | 0 | 0 | — |
| ALT (Grade 4) | 0 | 0 | 0 | — |
| Aspartate aminotransferase (AST) (Grade 1) | 1 | 0 | 0 | — |
| AST (Grade 2) | 0 | 0 | 0 | — |
| AST (Grade 3) | 0 | 0 | 0 | — |
| AST (Grade 4) | 0 | 0 | 0 | — |
| Alkaline phosphatase (ALP) (Grade 1) | 3 | 0 | 0 | — |
| ALP (Grade 2) | 0 | 0 | 0 | — |
| ALP (Grade 3) | 0 | 0 | 0 | — |
| ALP (Grade 4) | 0 | 0 | 0 | — |
| Creatinine (Grade 1) | 0 | 0 | 0 | — |
| Creatinine (Grade 2) | 0 | 0 | 0 | — |
| Creatinine (Grade 3) | 0 | 0 | 0 | — |
| Creatinine (Grade 4) | 0 | 0 | 0 | — |
| Total bilirubin (Grade 1) | 0 | 0 | 0 | — |
| Total bilirubin (Grade 2) | 0 | 0 | 0 | — |
| Total bilirubin (Grade 3) | 0 | 0 | 0 | — |
| Total bilirubin (Grade 4) | 0 | 0 | 0 | — |
| ng/mL | Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg/d | Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg/d | Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg/d | Ixabepilone + Lapatinib + Capecitabine |
|---|---|---|---|---|
| Maximum Concentration of Ixabepilone | 200.6 ± 78.4 | 109.2 ± 1.1 | 133.4 (133.4 to 133.4) | — |
| ng*h/mL | Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg/d | Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg/d | Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg/d | Ixabepilone + Lapatinib + Capecitabine |
|---|---|---|---|---|
| AUC(INF) | 2212.9 ± 1030.4 | 2427.0 ± 225.5 | 1610.7 | — |
| AUC(O-T) | 1851.8 ± 880.5 | 2082.0 ± 133.6 | 1284.2 | — |
| Hours | Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg/d | Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg/d | Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg/d | Ixabepilone + Lapatinib + Capecitabine |
|---|---|---|---|---|
| Terminal Half-life of Ixabepilone | 51.6 ± 13.2 | 63.1 ± 10.4 | 33.1 | — |
| Hours | Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg/d | Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg/d | Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg/d | Ixabepilone + Lapatinib + Capecitabine |
|---|---|---|---|---|
| Time to Peak Concentration of Ixabepilone | 3.0 (2.0 to 3.4) | 3.0 (3.0 to 3.0) | 2.9 (2.9 to 2.9) | — |
| Liters | Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg/d | Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg/d | Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg/d | Ixabepilone + Lapatinib + Capecitabine |
|---|---|---|---|---|
| Volume of Distribution at Steady State of Ixabepilone | 1484.3 ± 438.5 | 1780.8 ± 237.9 | 1915.8 | — |
MTD is defined as the maximum dose that can be administered to 6 participants such that no more than 1 (or fewer than one third if more than 6 participants receive treatment) experiences a DLT, with at least 2 experiencing a DLT at the next higher dose level. The RP2D is based on the MTD and the assessment of any relevant chronic toxicities.
No measurements were reported for this outcome.
Target lesion criteria: Complete Response(CR)=Disappearance of all clinical and radiologic evidence of target lesions; Partial Response (PR)=A 30% or greater decrease in the sum of longest diameter(LD) of all lesions in reference to the baseline sum LD. Stable Disease (SD)=Insufficient increase to qualify for Progressive Disease (PD) and insufficient shrinkage to qualify for PR; PD=A 20% or greater increase in the sum of LD of all target lesions, taking as reference the smallest sum LD recorded at or following baseline.
| Participants | Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg/d | Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg/d | Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg/d | Ixabepilone + Lapatinib + Capecitabine |
|---|---|---|---|---|
| CR | 3 ± 12.2 | 2 ± 2.1 | 0 | — |
| PR | 0 | 0 | 0 | — |
| SD | 3 | 1 | 1 | — |
| PD | 0 | 0 | 0 | — |
Duration of response is measured from the time in months that measurement criteria are first met for PR or CR, whichever is recorded first, until the date of documented PD or death. Participants who neither relapse nor die will be censored on the date of their last tumor assessment.
No measurements were reported for this outcome.
Collected over Baseline to Day 21, continuously. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg/d | — | 2/6 (33.3%) | 6/6 (100%) |
| Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg/d | — | 0/3 (0%) | 3/3 (100%) |
| Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg/d | — | 1/1 (100%) | 1/1 (100%) |
| Event | Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg/d | Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg/d | Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg/d |
|---|---|---|---|
| NAUSEAGastrointestinal disorders | 0/6 | 0/3 | 1/1 |
| VOMITINGGastrointestinal disorders | 0/6 | 0/3 | 1/1 |
| DIARRHOEAGastrointestinal disorders | 0/6 | 0/3 | 1/1 |
| URINARY TRACT INFECTIONInfections and infestations | 0/6 | 0/3 | 1/1 |
| DEHYDRATIONMetabolism and nutrition disorders | 0/6 | 0/3 | 1/1 |
| CHEST PAINGeneral disorders | 0/6 | 0/3 | 1/1 |
| DEVICE RELATED INFECTIONInfections and infestations | 1/6 | 0/3 | 0/1 |
| HYPOKALAEMIAMetabolism and nutrition disorders | 1/6 | 0/3 | 0/1 |
| DECREASED APPETITEMetabolism and nutrition disorders | 1/6 | 0/3 | 0/1 |
| ANAEMIABlood and lymphatic system disorders | 1/6 | 0/3 | 0/1 |
| Event | Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg/d | Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg/d | Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg/d |
|---|---|---|---|
| HAEMOGLOBIN DECREASEDInvestigations | 1/6 | 0/3 | 1/1 |
| INSOMNIAPsychiatric disorders | 2/6 | 0/3 | 1/1 |
| LETHARGYNervous system disorders | 1/6 | 0/3 | 1/1 |
| NAUSEAGastrointestinal disorders | 5/6 | 1/3 | 1/1 |
| VOMITINGGastrointestinal disorders | 3/6 | 0/3 | 1/1 |
| DIARRHOEAGastrointestinal disorders | 5/6 | 3/3 | 1/1 |
| CONSTIPATIONGastrointestinal disorders | 2/6 | 0/3 | 1/1 |
| ABDOMINAL PAINGastrointestinal disorders | 1/6 | 0/3 | 1/1 |
| URINARY TRACT INFECTIONInfections and infestations | 0/6 | 0/3 | 1/1 |
| MICTURITION URGENCYRenal and urinary disorders | 0/6 | 0/3 | 1/1 |
| Age, Customized(participants) | Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg | Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg | Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg | Ixabepilone + Lapatinib + Capecitabine | Total |
|---|---|---|---|---|---|
| Younger than 50 years | 1 | 1 | 0 | — | 2 |
| 50 years and older to younger than 65 years | 4 | 2 | 1 | — | 7 |
| 65 years and older | 1 | 0 | 0 | — | 1 |
| Gender(participants) | Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg | Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg | Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg | Ixabepilone + Lapatinib + Capecitabine | Total |
|---|---|---|---|---|---|
| Female | 6 | 3 | 1 | — | 10 |
| Male | 0 | 0 | 0 | — | 0 |
| Race (NIH/OMB)(participants) | Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg | Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg | Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg | Ixabepilone + Lapatinib + Capecitabine | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | — | 0 |
| Asian | 1 | 0 | 0 | — | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | — | 0 |
| Black or African American | 0 | 0 | 0 | — | 0 |
| White | 5 | 3 | 1 | — | 9 |
| More than one race | 0 | 0 | 0 | — | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | — | 0 |
The record gives a start of Jun 2008, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ixabepilone · Lapatinib · Capecitabine